Treatment of XXXX --a Swedish multicenter study.

@entity4444 @entity1 @entity1066 @entity4773 @entity5418
Medical ulcer therapy focuses on enhancing mucosal defence mechanisms or reducing intraluminal acidity. In this Swedish multicenter, randomized double-blind study these two principles were compared in the treatment of acute duodenal @entity1066 . @entity5418 (Andapsin 1g X 4) or @entity4444 (Tagamet 400mg X 2), together with antacid tablets (Novalucol), were supplied to @entity1 with acute @entity1066 in the pyloric ring or duodenal bulb. Endoscopy was performed at inclusion, after four weeks and in some @entity1 also after eight weeks. Besides healing rate, symptoms and antacid intake, smoking and side effects were recorded on a special protocol. 371 @entity1 from 15 centers completed the trial. At inclusion the @entity1 groups did not differ in any essential aspect. At four weeks 71% of 177 @entity1 on @entity5418 and 77% of 194 on @entity4444 were healed. The corresponding figures for eight weeks were 86% (suc) and 92% (cim). The difference is not significant, the 95% confidence interval for the difference in @entity1066 efficacy of @entity5418 compared with @entity4444 at eight weeks was -12% to +5%. Antacid intake and symptoms decreased rapidly and equally in both groups. Side effects related to the treatments were uncommon. It is concluded that @entity5418 and @entity4444 , representing two different principles in medical ulcer treatment, are both very effective and compare well in the short term treatment of @entity4773 .
